Zolimomab

Zolimomab is a type of monoclonal antibody that was designed for the treatment of cancer. It is also known as Zolimomab aritox and was developed by Peregrine Pharmaceuticals.

History

Zolimomab was one of the first monoclonal antibodies to be developed for the treatment of cancer. It was initially developed by Peregrine Pharmaceuticals, a biopharmaceutical company based in the United States. The development of Zolimomab began in the late 1990s and early 2000s.

Mechanism of Action

Zolimomab works by targeting and binding to a specific protein found on the surface of cancer cells. This protein, known as Phosphatidylserine, is typically found on the inside of healthy cells, but is exposed on the outside of cancer cells. Once Zolimomab binds to this protein, it triggers the immune system to attack and destroy the cancer cells.

Clinical Trials

Several clinical trials have been conducted to test the safety and efficacy of Zolimomab. These trials have included patients with various types of cancer, including lung cancer, breast cancer, and prostate cancer. While some trials have shown promising results, others have not met their primary endpoints.

Side Effects

Like all medications, Zolimomab can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and fever. In some cases, patients may also experience more serious side effects, such as allergic reactions or changes in blood pressure.

Current Status

As of 2021, Zolimomab is not currently approved for use by any health regulatory authority. However, research and development efforts continue, with the hope that Zolimomab may one day become a viable treatment option for patients with cancer.

Zolimomab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski